Paper Details
- Home
- Paper Details
Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival.
Author: , BardeguezArlene D, CoombsRobert, CunninghamBethann, FowlerMary Glenn, FrenkelLisa M, GandiaJorge, HuangSharon, JonesTheodore, MaupinRobert, MofensonLynne M, O'SullivanMary Jo, ShapiroDavid E, SperlingRhoda S, ZorrillaCarmen D
Original Abstract of the Article :
Zidovudine prophylaxis is recommended to reduce perinatal HIV-1 transmission, but there are limited data on long-term effects on women's health. Pediatrics AIDS Clinical Trials Group (PACTG) 288 was a prospective observational study among US women randomized to zidovudine or placebo in PACTG 076 tha...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1097/00126334-200302010-00009
データ提供:米国国立医学図書館(NLM)
Cessation of Zidovudine Prophylaxis for Vertical HIV Transmission: A Long-Term Study
Preventing mother-to-child transmission of HIV is a major public health goal. This study, like a long-term desert expedition tracking the effects of a change in the environment, investigates the long-term effects of ceasing zidovudine prophylaxis, a common treatment for reducing vertical HIV transmission, on maternal HIV disease progression and survival. The researchers conducted a prospective observational study, following women who had been randomized to receive zidovudine or placebo in a previous trial. They found that the cessation of zidovudine prophylaxis did not significantly affect maternal HIV disease progression or survival.
Long-Term Impact of Zidovudine Prophylaxis
The study's findings offer reassuring news about the long-term impact of zidovudine prophylaxis on maternal HIV disease progression and survival. The results suggest that the cessation of prophylaxis, even after years of treatment, does not significantly increase the risk of disease progression or death.
Navigating Treatment Decisions for HIV-Infected Pregnant Women
This study provides valuable information for clinicians who are making treatment decisions for HIV-infected pregnant women. The findings suggest that a careful assessment of individual patient factors, including viral load and CD4 cell count, can guide decisions about the appropriate duration of zidovudine prophylaxis.
Dr. Camel's Conclusion
This study, like a beacon of hope illuminating the path through a challenging desert, provides valuable information for clinicians and patients alike. The findings offer reassurance about the long-term safety of ceasing zidovudine prophylaxis for reducing vertical HIV transmission, while also emphasizing the importance of individualized patient care. As we continue to navigate the evolving landscape of HIV treatment, this study serves as a reminder that scientific advancements can lead to improved outcomes for both mothers and children.
Date :
- Date Completed 2003-03-12
- Date Revised 2020-09-30
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.